Clinical Data, Safety and Statistical Centers (CDSSC)

The National Institutes of Health (NIH), within the U.S. Department of Health and Human Services, is forecasting a funding opportunity titled Clinical Data, Safety and Statistical Centers (CDSSC). This program is administered through the National Institute of Allergy and Infectious Diseases (NIAID), specifically supporting the Division of Allergy, Immunology, and Transplantation. NIH is the primary federal agency responsible for biomedical and public health research in the United States, and NIAID plays a leading role in advancing scientific understanding and treatment of infectious, immunologic, and allergic diseases. This opportunity reflects NIH’s continued investment in infrastructure that supports large-scale clinical research and coordinated scientific initiatives. The purpose of the CDSSC program is to provide comprehensive coordination, oversight, and analytical support for clinical research activities funded by NIAID. The centers funded under this opportunity will support a wide range of operational and scientific functions, including statistical design, protocol development, study implementation, and data analysis. The scope includes facilitating research across three major disease areas: asthma and allergy, autoimmune diseases, and transplantation. These centers are expected to serve multiple clinical networks and programs simultaneously, ensuring consistency, rigor, and efficiency in study execution and reporting. Funding will support activities such as study initiation and management, data management systems, safety monitoring processes, sample tracking, and final analysis of study outcomes. Additionally, awardees will contribute to the development of manuscripts and dissemination of findings. The funding is structured as a cooperative agreement, indicating substantial involvement from NIH program staff in project oversight and execution. There is no cost-sharing or matching requirement specified, allowing applicants to focus resources on programmatic execution rather than financial contribution requirements. Eligibility for this opportunity is broad and inclusive, encompassing a wide range of organizational types. Eligible applicants include institutions of higher education (both public and private), nonprofit organizations with or without 501(c)(3) status, for-profit entities, small businesses, and various levels of government including state, county, city, and tribal governments. Additional eligible entities include public housing authorities, independent school districts, special district governments, regional organizations, faith-based organizations, and non-U.S. entities. This broad eligibility framework reflects NIH’s intent to attract diverse and capable institutions with the infrastructure necessary to manage complex clinical research coordination efforts. The application process is expected to follow standard NIH submission procedures, likely requiring detailed proposals outlining organizational capacity, technical expertise, and proposed methodologies for managing clinical data and safety operations. While specific application components are not yet detailed in this forecast, typical NIH cooperative agreement applications include research plans, budget justifications, biosketches, and institutional resources descriptions. Applicants will likely be evaluated based on scientific and technical merit, organizational capability, and alignment with program goals. The timeline for this opportunity is currently forecasted, with an estimated posting date of February 1, 2027, and an application due date of June 1, 2027. Awards are anticipated to be made by May 1, 2028, with project start dates aligned to the same timeframe. As a forecasted opportunity, this announcement allows prospective applicants to begin early planning and engagement. Communication with the program is facilitated through an official NIH email contact, and applicants are encouraged to monitor updates as the opportunity progresses toward formal release. There is no explicit indication of recurrence, suggesting this may be a periodic but not strictly annual funding mechanism.